<div id="readability-page-1"><p>In a report released yesterday, Geulah Livshits from Chardan Capital reiterated a Buy rating on Crispr Therapeutics AG, with a price target of <span id="expert-recommendation-target">$76.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Livshits is a 5-star analyst with an average return of <span>12.7%</span> and a 37.88% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Iovance Biotherapeutics, and Rocket Pharmaceuticals.</p> <p>The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $72.33 average price target.</p></div>

CRSP

ARKG

LABU

IDNA

<p>Chardan Capital has reiterated a Buy rating on Crispr Therapeutics AG (CRSP) with a price target of $76.00. Analyst Geulah Livshits, a 5-star analyst with a 12.7% average return, highlights a Moderate Buy consensus rating for the stock, with an average price target of $72.33. Livshits also covers other healthcare stocks like Palvella Therapeutics and Iovance Biotherapeutics.</p>

Tip Ranks

CRISPR Therap

SPDR S&P Biotech

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Genomics Immunology and Healthcare ETF

First Trust NYSE Arca Biotech Index Fd

Palvella Therapeutics

Iovance Biotherapeautics

Rocket Pharma

ROCKET PHARMACEUTICALS INC C/WTS 02/09/2026 (TO PUR COM)

Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP)